At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 93 enrolled
Drug / intervention
Rebif®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device
In Brief
A Phase 4 clinical trial evaluating Rebif® for Multiple Sclerosis and Relapsing-Remitting. Completed, enrolled 93 participants across 14 sites in 2 countries.
Detailed Summary
This is a randomized, comparative, and multicenter study to assess the impact of a patient support program (MinSupport Plus) on health related quality of life (HRQoL) and adherence in subjects with relapsing-remitting multiple sclerosis administered Rebif® with the RebiSmart™ device.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Relapsing-Remitting
CountriesGermany, Sweden
Collaborators--
Timeline
Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartFeb 2013
Primary CompletionFeb 2016
TodayJul 2026
First PostedFeb 13, 2013
Enrollment StartFeb 28, 2013
Primary CompletionFeb 29, 2016
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 13.4 years ago
Interventions
Rebif®drug